Nebenwirkungen · Enhertu
Enhertu 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-144503 · Präparat HOS-099200
Dose interruptions due to adverse reactions occurred in 34.3% of patients treated with Enhertu. The most frequent adverse reactions associated with dose interruption were neutropenia (12.7%), fatigue (4.4%), anaemia (4.3%), upper respiratory tract infection (3.8%), leukopenia (3.1%), ILD/pneumonitis (3.0%), thrombocytopenia (2.8%) and pneumonia (2.5%). Dose reductions occurred in 21.1% of patients treated with Enhertu. The most frequent adverse reactions associated with dose reduction were
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:27:00Z · SHA-256 3c4c744afc1ef29bbcad254e39bd7fd8b4be34bb4ddecf254258c2ab2c9863c8 · Passage 2d1a2ccf64a8ec29f80c2c145f7c460ff52be1b2269576ff2478a51326b4caa6 · Zeichen 1206–1700 im Abschnitt